Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


EMA Knocks Back Pfizer’s Xeljanz For Rheumatoid Arthritis and Otsuka’s Delamanid For TB

This article was originally published in The Pink Sheet Daily

Executive Summary

The EMA has rejected Pfizer’s tofacitinib for the second time on safety grounds and Otsuka’s delamanid due to a short trial length.


Related Content

Pfizer's Xeljanz Set To Lag Lilly's Olumiant In Europe Following Past Rebuffs
India’s Drug Advisory Body Calls For Larger Study To Approve Pfizer’s Xeljanz
EMA Birth Control Safety Review Shows PRAC’s Clout, Concern About Newer Products


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts